![\"C16H26ClNO2\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/C16H26ClNO2.jpg\")
<\/p>\n(Ph. Eur. 11.6 update)<\/p>\n
(Ph. Eur. monograph 1681)<\/p>\n
<\/p>\n
C16<\/sub>H26<\/sub>ClNO2<\/sub>\u00a0 \u00a0 \u00a0 \u00a0299.8\u00a0 \u00a036282-47-0<\/p>\n Action and use<\/strong><\/p>\n \u03bc-Opioid receptor (OP3, MOR) agonist and noradrenaline reuptake inhibitor; analgesic.<\/p>\n Preparations<\/strong><\/p>\n Tramadol Capsules<\/p>\n Tramadol Prolonged-release Capsules<\/p>\n Tramadol Injection<\/p>\n Tramadol Oral Drops<\/p>\n Tramadol Prolonged-release Tablets<\/p>\n Ph Eur<\/p>\n (1RS,2RS)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol hydrochloride.<\/p>\n Content<\/strong><\/p>\n 99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n Appearance<\/strong><\/p>\n White or almost white, crystalline powder.<\/p>\n Solubility<\/strong><\/p>\n Freely soluble in water and in methanol, very slightly soluble in acetone.<\/p>\n First identification: B, D.<\/p>\n Second identification: A, C, D.<\/p>\n A. Melting point (2.2.14): 180 \u00b0C to 184 \u00b0C.<\/p>\n B. Infrared absorption spectrophotometry (2.2.24). Comparison tramadol hydrochloride CRS.<\/p>\n C. Examine the chromatograms obtained in the test for impurity E. Results: The principal spot in the chromatogram obtained with test solution (b) is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).<\/p>\n D. It gives reaction (a) of chlorides (2.3.1).<\/p>\n Solution S<\/strong><\/p>\n Dissolve 1.0 g in water R and dilute to 20.0 mL with the same solvent.<\/p>\n Appearance of solution<\/strong><\/p>\n Solution S is clear (2.2.1) and colourless (2.2.2, Method II).<\/p>\n Acidity<\/strong><\/p>\n To 10 mL of solution S, add 0.2 mL of methyl red solution R and 0.2 mL of 0.01 M hydrochloric acid. The solution is red. Not more than 0.4 mL of 0.01 M sodium hydroxide is required to change the colour of the indicator to yellow.<\/p>\n Optical rotation (2.2.7)<\/p>\n -0.10\u00b0 to +0.10\u00b0, determined on solution S.<\/p>\n Impurity E<\/strong><\/p>\n Thin-layer chromatography (2.2.27).<\/p>\n Test solution (a) Dissolve 0.10 g of the substance to be examined in methanol R and dilute to 2.0 mL with the same solvent.<\/p>\n Test solution (b) Dilute 1 mL of test solution (a) to 10 mL with methanol R.<\/p>\n Reference solution (a) Dissolve 25 mg of tramadol hydrochloride CRS in methanol R and dilute to 5 mL with the same solvent.<\/p>\n Reference solution (b) Dissolve 5.0 mg of tramadol impurity E CRS in methanol R and dilute to 5.0 mL with the same solvent. Dilute 1.0 mL of the solution to 10.0 mL with methanol R.<\/p>\n Reference solution (c) Dissolve 5 mg of tramadol impurity A CRS in 1 mL of reference solution (a).<\/p>\n Plate TLC silica gel F254 plate R.<\/p>\n Pretreatment.\u00a0 Wash the plate with methanol R.<\/p>\n Mobile phase\u00a0 Concentrated ammonia R, 2-propanol R, toluene R (1:19:80 V\/V\/V).<\/p>\n Application. 10 \u03bcL.<\/p>\n Development. Over 2\/3 of the plate. Add concentrated ammonia R to one trough of a twin trough tank then saturate the plate for 20 min. Just before developing, add the mobile phase to the other trough. Place the plate in the trough, ensuring that the layer of silica gel faces the middle of the tank.<\/p>\n Drying. In air.<\/p>\n Detection.\u00a0 Expose to iodine vapour for 1 h, then examine in ultraviolet light at 254 nm.<\/p>\n System suitability.\u00a0 The chromatogram obtained with reference solution (c) shows 2 clearly separated spots.<\/p>\n Limit Test solution (a)<\/p>\n \u2014 impurity E: any spot due to impurity E is not more intense than the spot in the chromatogram obtained with reference solution (b) (0.2 per cent).<\/p>\n Related substances<\/strong><\/p>\n Liquid chromatography (2.2.29).<\/p>\n Test solution\u00a0 \u00a0Dissolve 0.15 g of the substance to be examined in the mobile phase and dilute to 100.0 mL with the mobile phase.<\/p>\n Reference solution (a).\u00a0 Dilute 2.0 mL of the test solution to 10.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 100.0 mL with the mobile phase.<\/p>\n Reference solution (b).\u00a0 Dissolve 5 mg of tramadol impurity A CRS in 4 mL of the test solution and dilute to 100 mL with the mobile phase.<\/p>\n Column<\/p>\n \u2014 size: l = 0.25 m, \u00d8 = 4.0 mm;<\/p>\n \u2014 stationary phase: base-deactivated end-capped octylsilyl silica gel for chromatography R (5 \u03bcm).<\/p>\n Mobile phase<\/p>\n 295 volumes of acetonitrile R and 705 volumes of a mixture of 0.2 mL of trifluoroacetic acid R and 100 mL of water for chromatography R.<\/p>\n Flow rate\u00a0 \u00a01.0 mL\/min.<\/p>\n Detection. Spectrophotometer at 270 nm.<\/p>\n Injection.\u00a0 20 \u03bcL.<\/p>\n Run time. 4 times the retention time of tramadol.<\/p>\n Identification of impurities. Use the chromatogram obtained with reference solution (b) to identify the peak due to impurity A.<\/p>\n Relative retention\u00a0 \u00a0With reference to tramadol (retention time = about 6 min): impurity A = about 0.85.<\/p>\n System suitability. Reference solution (b): resolution: minimum 2.0 between the peaks due to impurity A and tramadol.<\/p>\n Calculation of percentage contents<\/p>\n \u2014 for each impurity, use the concentration of tramadol hydrochloride in reference solution (a).<\/p>\n Limits<\/p>\n \u2014 impurity A: maximum 0.2 per cent;<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total: maximum 0.4 per cent;<\/p>\n \u2014 reporting threshold: 0.02 per cent.<\/p>\n Water (2.5.12)<\/p>\n Maximum 0.5 per cent, determined on 1.000 g.<\/p>\n Sulfated ash (2.4.14)<\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n Dissolve 0.180 g in 50 mL of ethanol (96 per cent) R. Titrate with 0.1 M ethanolic sodium hydroxide, determining the end-point potentiometrically (2.2.20).<\/p>\n 1 mL of 0.1 M ethanolic sodium hydroxide is equivalent to 29.98 mg of C16H26ClNO2.<\/p>\n Protected from light.<\/p>\n Specified impurities A, E.<\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, C, D.<\/p>\n A. (1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol,<\/p>\n B. [2-(3-methoxyphenyl)cyclohex-1-en-1-yl]-N,N-dimethylmethanamine,<\/p>\n C. [(1RS)-2-(3-methoxyphenyl)cyclohex-2-en-1-yl]-N,N-dimethylmethanamine,<\/p>\n D. (1RS,2RS)-2-[(dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexan-1-ol,<\/p>\n E. (2RS)-2-[(dimethylamino)methyl]cyclohexan-1-one.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. 11.6 update) (Ph. Eur. monograph 1681) C16H26ClNO2\u00a0 \u00a0 \u00a0 \u00a0299.8\u00a0 \u00a036282-47-0 Action and use \u03bc-Opioid receptor (OP3, MOR) agonist and noradrenaline reuptake inhibitor; analgesic. Preparations Tramadol Capsules Tramadol Prolonged-release Capsules Tramadol Injection Tramadol Oral Drops Tramadol Prolonged-release Tablets Ph Eur DEFINITION (1RS,2RS)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol hydrochloride. Content 99.0 per cent to 101.0 per cent (anhydrous substance)….<\/p>\n","protected":false},"author":4,"featured_media":31383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-31376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=31376"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31376\/revisions"}],"predecessor-version":[{"id":31386,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31376\/revisions\/31386"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/31383"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=31376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=31376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=31376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
CHARACTERS<\/h2>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
ASSAY<\/h2>\n
STORAGE<\/h2>\n
IMPURITIES<\/h2>\n
![\"A.](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/A.-1RS2SR-2-dimethylaminomethyl-1-3-methoxyphenylcyclohexan-1-ol.jpg\")
<\/p>\n![\"B.](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/B.-2-3-methoxyphenylcyclohex-1-en-1-yl-NN-dimethylmethanamine.jpg\")
<\/p>\n![\"C.](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/C.-1RS-2-3-methoxyphenylcyclohex-2-en-1-yl-NN-dimethylmethanamine.jpg\")
<\/p>\n![\"D.](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/D.-1RS2RS-2-dimethylaminomethyl-1-3-hydroxyphenylcyclohexan-1-ol.jpg\")
<\/p>\n![\"E.](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/11\/E.-2RS-2-dimethylaminomethylcyclohexan-1-one.jpg\")
<\/p>\n